433 and 0.438, respectively; both p < 0.001). In multivariate analysis, QFT-GIT1 response was the only independent factor (odds ratio [OR]: 2.41, 95% CI: 1.23–4.72, per 1 IU/ml increment, p = 0.010) predicting persistent QFT-GIT positivity (non-reversion). For QFT-GIT1-positive patients, ROC curve analysis showed an AUC of 0.815 (p < 0.001) by QFT-GIT1 response for predicting persistent QFT-GIT positivity. The optimal cut-off value of QFT-GIT1 response was 0.93 IU/ml. The QFT-GIT1 response was <0.93 IU/ml in 67% and 79% of patients with reversion at 6-month and 12-month follow-up, respectively. For QFT-GIT2-positive

patients, QFT-GIT2 response was the only independent factor predicting QFT-GIT3 positivity (OR: 83.77, Apoptosis inhibitor 95% CI: 4.79–1466.38, per 1 IU/ml increment, p = 0.002). The AUC was 0.957 (p < 0.001) by ROC curve analysis and the optimal cut-off value of QFT-GIT2 was 0.95 IU/ml. No clinical characteristics were independently

associated with QFT-GIT conversion in multivariate analysis, although prior TB history had borderline significance (OR: 6.35, 95% CI: 0.846–47.67, p = 0.072). The present cohort study is the first to focus on dynamic changes of QFT-GIT in a dialysis population. The overall six-month reversion rate is high (45.9%), especially in those with recent positivity (87.5%). The QFT-GIT response is significantly different between reversion cases and persistently positive patients. A QFT response ≥0.93 IU/ml predicts Screening Library consistent positive QFT-GIT. Conversion is associated with prior TB and has a rate of 7.7% within 6 months. The reversion rate of 45.9% within 6 months in dialysis patients is higher than that in health care workers (33% at 18 weeks) and TB contacts (35% in 6 months) in previous reports.15 and 25 This may be due to within-subject variations or easy negative reversion caused by an immuno-compromised status.14, 19, 20 and 26 With longitudinal follow-up, the 6-month reversion rate becomes very different between patients ADAMTS5 with recent

positivity (87.5%) and those with remote positivity (20.8%). Assuming that reversion occurs as an exponential decay, the half-life of QFT-GIT positivity is around 2 and 18 months, respectively. The proportion of patients with remote positivity in the QFT-GIT positive population can be calculated as 62.4% (95% CI: 49.0–90.7%) by the following formula: RRoverall=Premotepositivity×RRremotepositivity+Precentpositivity×RRrecentpositivity,where RR stands for reversion rate and P is the proportion of patients. When overall reversion is balanced by conversion, the prevalence of QFT-GIT positivity is likewise stable. However, the decline in QFT-GIT positive rate in this one-year observational study may be due to a high reversion rate and underestimation of conversion. The high reversion may be due to the attenuated cellular immunity in dialysis patients, leading to rapid reversion after a transient infection.